A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577.

ABSTRACT:

Background

Results of CheckMate 577 show an improved disease-free survival for patients with resected esophageal or gastroesophageal junction cancer treated with adjuvant nivolumab compared with placebo (22.4 versus 11.0 months). Population-based data can provide insights in outcomes from clinical practice. The aim of our study was to investigate disease-free and overall survival in a nationwide population aligned with the inclusion criteria of CheckMate 577.

Patients and methods

Resected patients with stage II/III esophageal or gastroesophageal junction cancer (2015-2016) treated with neoadjuvant chemoradiotherapy were selected from the Netherlands Cancer Registry. Patients with cervical esophageal cancer, irradical resection, or complete pathological response were e

SUBMITTER: Pape M 

PROVIDER: S-EPMC8883292 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature